Pneumatosis intestinalis and pneumoperitoneum secondary to treatment with lenvatinib
Pneumatosis intestinalis is a rare disorder that can be secondary to a variety of causes among which includes oncological treatment. Most cases due to oncological treatment are reported with targeted therapy but there is growing number of cases secondary to tyrosin kinase inhibitors that includes Le...
Gespeichert in:
| Veröffentlicht in: | Revista española de enfermedades digestivas 2024-11 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | Revista española de enfermedades digestivas |
| container_volume | |
| creator | Benabdallah Sebbagh, Rania Del Pozo Prieto, David Beceiro Pedreño, Inmaculada Trueba Collado, Celia Salinas Núñez, Fernán Manuel González Sánchez-Ocaña, Lucía Castellano López, Amelia Tabernero da Veiga, Susana |
| description | Pneumatosis intestinalis is a rare disorder that can be secondary to a variety of causes among which includes oncological treatment. Most cases due to oncological treatment are reported with targeted therapy but there is growing number of cases secondary to tyrosin kinase inhibitors that includes Lenvatinib which it can be used in the treatment of hepatocarcinoma. |
| doi_str_mv | 10.17235/reed.2024.10908/2024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3130210501</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3130210501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1026-f609a197e2b63f3e41c34c2123b952a1cf5f82204877a0f650d915fb46a42aef3</originalsourceid><addsrcrecordid>eNo1kMtOwzAQRb0A0VL4BFCWbNKO7TiJl6jiJVWCRVlbTmILo8QOtgPi73Haspo7mrnzOAjdYFjjilC28Up1awKkWGPgUG9meYaWGFPIAUO9QJchfAIUtGTkAi0oZ4xzXC7R_s2qaZDRBRMyY6MK0VjZp0TaLhvnohuVN9HNMguqdbaT_jeLLoteyTgoG7MfEz-yXtlvmdymuULnWvZBXZ_iCr0_Puy3z_nu9elle7_LWwykzHUJXGJeKdKUVFNV4JYWLcGENpwRiVvNdE0IFHVVSdAlg45jppuilAWRStMVujvOHb37mtLpYjChVX0vrXJTEDT9TzAwwKmVHVtb70LwSovRmyE9IjCIA0QxQxQzOXGAeJDJd3taMTVDqv-7_gnSP5WPcYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130210501</pqid></control><display><type>article</type><title>Pneumatosis intestinalis and pneumoperitoneum secondary to treatment with lenvatinib</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Benabdallah Sebbagh, Rania ; Del Pozo Prieto, David ; Beceiro Pedreño, Inmaculada ; Trueba Collado, Celia ; Salinas Núñez, Fernán Manuel ; González Sánchez-Ocaña, Lucía ; Castellano López, Amelia ; Tabernero da Veiga, Susana</creator><creatorcontrib>Benabdallah Sebbagh, Rania ; Del Pozo Prieto, David ; Beceiro Pedreño, Inmaculada ; Trueba Collado, Celia ; Salinas Núñez, Fernán Manuel ; González Sánchez-Ocaña, Lucía ; Castellano López, Amelia ; Tabernero da Veiga, Susana</creatorcontrib><description>Pneumatosis intestinalis is a rare disorder that can be secondary to a variety of causes among which includes oncological treatment. Most cases due to oncological treatment are reported with targeted therapy but there is growing number of cases secondary to tyrosin kinase inhibitors that includes Lenvatinib which it can be used in the treatment of hepatocarcinoma.</description><identifier>ISSN: 1130-0108</identifier><identifier>DOI: 10.17235/reed.2024.10908/2024</identifier><identifier>PMID: 39559916</identifier><language>eng</language><publisher>Spain</publisher><ispartof>Revista española de enfermedades digestivas, 2024-11</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1026-f609a197e2b63f3e41c34c2123b952a1cf5f82204877a0f650d915fb46a42aef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39559916$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Benabdallah Sebbagh, Rania</creatorcontrib><creatorcontrib>Del Pozo Prieto, David</creatorcontrib><creatorcontrib>Beceiro Pedreño, Inmaculada</creatorcontrib><creatorcontrib>Trueba Collado, Celia</creatorcontrib><creatorcontrib>Salinas Núñez, Fernán Manuel</creatorcontrib><creatorcontrib>González Sánchez-Ocaña, Lucía</creatorcontrib><creatorcontrib>Castellano López, Amelia</creatorcontrib><creatorcontrib>Tabernero da Veiga, Susana</creatorcontrib><title>Pneumatosis intestinalis and pneumoperitoneum secondary to treatment with lenvatinib</title><title>Revista española de enfermedades digestivas</title><addtitle>Rev Esp Enferm Dig</addtitle><description>Pneumatosis intestinalis is a rare disorder that can be secondary to a variety of causes among which includes oncological treatment. Most cases due to oncological treatment are reported with targeted therapy but there is growing number of cases secondary to tyrosin kinase inhibitors that includes Lenvatinib which it can be used in the treatment of hepatocarcinoma.</description><issn>1130-0108</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo1kMtOwzAQRb0A0VL4BFCWbNKO7TiJl6jiJVWCRVlbTmILo8QOtgPi73Haspo7mrnzOAjdYFjjilC28Up1awKkWGPgUG9meYaWGFPIAUO9QJchfAIUtGTkAi0oZ4xzXC7R_s2qaZDRBRMyY6MK0VjZp0TaLhvnohuVN9HNMguqdbaT_jeLLoteyTgoG7MfEz-yXtlvmdymuULnWvZBXZ_iCr0_Puy3z_nu9elle7_LWwykzHUJXGJeKdKUVFNV4JYWLcGENpwRiVvNdE0IFHVVSdAlg45jppuilAWRStMVujvOHb37mtLpYjChVX0vrXJTEDT9TzAwwKmVHVtb70LwSovRmyE9IjCIA0QxQxQzOXGAeJDJd3taMTVDqv-7_gnSP5WPcYw</recordid><startdate>20241119</startdate><enddate>20241119</enddate><creator>Benabdallah Sebbagh, Rania</creator><creator>Del Pozo Prieto, David</creator><creator>Beceiro Pedreño, Inmaculada</creator><creator>Trueba Collado, Celia</creator><creator>Salinas Núñez, Fernán Manuel</creator><creator>González Sánchez-Ocaña, Lucía</creator><creator>Castellano López, Amelia</creator><creator>Tabernero da Veiga, Susana</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241119</creationdate><title>Pneumatosis intestinalis and pneumoperitoneum secondary to treatment with lenvatinib</title><author>Benabdallah Sebbagh, Rania ; Del Pozo Prieto, David ; Beceiro Pedreño, Inmaculada ; Trueba Collado, Celia ; Salinas Núñez, Fernán Manuel ; González Sánchez-Ocaña, Lucía ; Castellano López, Amelia ; Tabernero da Veiga, Susana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1026-f609a197e2b63f3e41c34c2123b952a1cf5f82204877a0f650d915fb46a42aef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Benabdallah Sebbagh, Rania</creatorcontrib><creatorcontrib>Del Pozo Prieto, David</creatorcontrib><creatorcontrib>Beceiro Pedreño, Inmaculada</creatorcontrib><creatorcontrib>Trueba Collado, Celia</creatorcontrib><creatorcontrib>Salinas Núñez, Fernán Manuel</creatorcontrib><creatorcontrib>González Sánchez-Ocaña, Lucía</creatorcontrib><creatorcontrib>Castellano López, Amelia</creatorcontrib><creatorcontrib>Tabernero da Veiga, Susana</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Revista española de enfermedades digestivas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Benabdallah Sebbagh, Rania</au><au>Del Pozo Prieto, David</au><au>Beceiro Pedreño, Inmaculada</au><au>Trueba Collado, Celia</au><au>Salinas Núñez, Fernán Manuel</au><au>González Sánchez-Ocaña, Lucía</au><au>Castellano López, Amelia</au><au>Tabernero da Veiga, Susana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pneumatosis intestinalis and pneumoperitoneum secondary to treatment with lenvatinib</atitle><jtitle>Revista española de enfermedades digestivas</jtitle><addtitle>Rev Esp Enferm Dig</addtitle><date>2024-11-19</date><risdate>2024</risdate><issn>1130-0108</issn><abstract>Pneumatosis intestinalis is a rare disorder that can be secondary to a variety of causes among which includes oncological treatment. Most cases due to oncological treatment are reported with targeted therapy but there is growing number of cases secondary to tyrosin kinase inhibitors that includes Lenvatinib which it can be used in the treatment of hepatocarcinoma.</abstract><cop>Spain</cop><pmid>39559916</pmid><doi>10.17235/reed.2024.10908/2024</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1130-0108 |
| ispartof | Revista española de enfermedades digestivas, 2024-11 |
| issn | 1130-0108 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3130210501 |
| source | EZB-FREE-00999 freely available EZB journals |
| title | Pneumatosis intestinalis and pneumoperitoneum secondary to treatment with lenvatinib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A55%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pneumatosis%20intestinalis%20and%20pneumoperitoneum%20secondary%20to%20treatment%20with%20lenvatinib&rft.jtitle=Revista%20espa%C3%B1ola%20de%20enfermedades%20digestivas&rft.au=Benabdallah%20Sebbagh,%20Rania&rft.date=2024-11-19&rft.issn=1130-0108&rft_id=info:doi/10.17235/reed.2024.10908/2024&rft_dat=%3Cproquest_cross%3E3130210501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130210501&rft_id=info:pmid/39559916&rfr_iscdi=true |